Continuous versus inpatient prophylaxis of the first episode of spontaneous bacterial peritonitis with norfloxacin

Hepatology

Volumn 25, Issue 3, 1997, Pages 532-536

  Novella, Maite ^a   Solà, Ricard ^b   Soriano, German ^a   Andreu, Montserrat ^b   Gana, Jordi ^b   Ortiz, Jordi ^a   Coll, Susana ^b   Sàbat, Miriam ^a   Vila, Maria Carme ^b   Guarner, Carlos ^a   Vilardell, Francisco ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b HOSPITAL DEL MAR   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CEFOTAXIME; CIPROFLOXACIN; COTRIMOXAZOLE; NORFLOXACIN;

ADULT; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BACTERIAL PERITONITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HOSPITAL PATIENT; HUMAN; INFECTION RATE; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ANTI-INFECTIVE AGENTS; ASCITES; BACTERIAL INFECTIONS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, MICROBIAL; FEMALE; FOLLOW-UP STUDIES; HOSPITALIZATION; HUMANS; INCIDENCE; LIVER CIRRHOSIS; MALE; MIDDLE AGED; NORFLOXACIN; PERITONITIS;

EID: 0031050204     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.510250306     Document Type: Article

References (20)

1. Hoefs JC, Runyon BA. Spontaneous bacterial peritonitis. Dis Mon 1985;31:1-48.
2. Runyon BA. Low-protein-concentration ascitic fluid is predisposed to spontaneous bacterial peritonitis. Gastroenterology 1986;91:1343-1346.
3. Such J, Guarner C, Enríquez J, Rodríguez JL, Serés I, Vilardell F. Low C3 in ascitic fluid predisposes to spontaneous bacterial peritonitis. J Hepatol 1988;6:80-84.
4. Soriano G, Guarner C, Teixidó M, Such J, Barrios J, Enríquez J, Vilardell F. Selective intestinal decontamination prevents spontaneous bacterial peritonitis. Gastroenterology 1991;100:477-481.
5. Andreu M, Solà R, Sitges-Serra A, Alia C, Gallen M, Vila MC, Coll S, et al. Risk factors for spontaneous bacterial peritonitis in cirrhotic patients with ascites. Gastroenterology 1993;104:1133-1138.
6. Llach J, Rimola A, Navasa M, Ginès P, Salmerón JM, Ginès A, Arroyo V, et al. Incidence and predictive factors of first episode of spontaneous bacterial peritonitis in cirrhosis with ascites: relevance of ascitic fluid protein concentration. HEPATOLOGY 1992;16:724-727.
7. Guarner C, Runyon BA. Spontaneous bacterial peritonitis: pathogenesis, diagnosis, and management. Gastroenterologist 1995;3:311-328.
8. Gilbert JA, Kamath PS. Spontaneous bacterial peritonitis: an update. Mayo Clin Proc 1995;70:365-370.
9. Felisart J, Rimola A, Arroyo V, Pérez-Ayuso RM, Quintero E, Ginès P, Rodés J. Cefotaxime is more effective than is ampicillin-tobramycin in cirrhotics with severe infections. HEPATOLOGY 1985;5:457-462.
10. Toledo C, Salmerón JM, Rimola A, Navasa M, Arroyo V, Llach J, Ginès A, et al. Spontaneous bacterial peritonitis in cirrhosis: predictive factors of infection resolution and survival in patients treated with cefotaxime. HEPATOLOGY 1993;17:251-257.
11. Llovet JM, Planas R, Morillas R, Quer JC, Cabré E, Boix J, Humbert P, et al. Short-term prognosis of cirrhotics with spontaneous bacterial peritonitis: multivariate study. Am J Gastroenterol 1993;88:388-392.
12. Titó LI, Rimola A, Ginès P, Llach J, Arroyo V, Rodés J. Recurrence of spontaneous bacterial peritonitis in cirrhosis: frequency and predictive factors. HEPATOLOGY 1988;8:27-31.
13. Rimola A, Bory F, Planas R, Xaubet A, Bruguera M, Rodés J. Infecciones bacterianas en la cirrosis hepática. Gastroenterol Hepatol 1981;4:453-458.
14. Caly WR, Strauss E. A prospective study of bacterial infections in patients with cirrhosis. J Hepatol 1993;18:353-358.
15. Rimola A, Bory F, Terés J, Pérez-Ayuso RM, Arroyo V, Rodés J. Oral, nonabsorbable antibiotics prevent infection in cirrhotics with gastrointestinal hemorrhage. HEPATOLOGY 1985;5:463-467.
16. Ginés P, Rimola A, Planas R, Vargas V, Marco F, Almela M, Forné M, et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial. HEPATOLOGY 1990;12:716-724.
17. Such J, Guarner C, Soriano G, Teixidó M, Barrios J, Tena F, Méndez C, et al. Selective intestinal decontamination increases serum and ascitic fluid C3 levels in cirrhosis. HEPATOLOGY 1990;12:1175-1178.
18. van der Waaij D, Manson WL, Arends JP, de Vries Hospers HG. Clinical use of selective decontamination: the concept. Intensive Care Med 1990;16(suppl 3):S212-216.
19. Neuman M. Clinical pharmacokinetics of the newer antibacterial 4-quinolones. Clin Pharmacokinet 1988;14:96-121.
20. Soriano G, Guarner C, Tomás A, Villanueva C, Torras X, González D, Sainz S, et al. Norfloxacin prevents bacterial infection in cirrhotics with gastrointestinal bleeding. Gastroenterology 1992;103:1267-1272.